MedTrace Logo

A Study Of The Selective PKC-β Inhibitor MS- 553

NCT03492125 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-10

Study results available
· View outcomes & findings →

Summary

A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions

Interventions

DRUG

MS-553

Oral, multiple dose levels

DRUG

MS-553

Oral recommended phase 2 dose of MS-553

DRUG

acalabrutinib

Oral

DRUG

venetoclax

Oral

DRUG

Rituximab

IV

DRUG

obinutuzumab

IV

Sponsors & Collaborators

  • MingSight Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2023-11-28
Completion
2023-11-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03492125 on ClinicalTrials.gov